Kane Biotech Appoints Dr. Gregory Schultz as Chief Scientific Officer
05. April 2022 08:00 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, April 05, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), announced today the appointment of Gregory Schultz, PhD, a world...
Kane Biotech Announces Fourth Quarter and Full Year 2021 Financial Results
24. März 2022 16:05 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, March 24, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), today announced its fourth quarter and full year 2021 financial...
Kane Biotech Successfully Completes Safety and Biocompatibility Studies for DispersinB® Wound Gel in Preparation for Human Clinical Trials
22. März 2022 08:00 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, March 22, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech,” or “the Company”) announced positive results from biocompatibility and in vivo...
Kane Biotech to Release Fourth Quarter and Full Year 2021 Financial Results on March 24 – Conference Call to Follow
17. März 2022 07:00 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, March 17, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and...
Kane Biotech Announces Private Placement Offering
15. März 2022 07:00 ET
|
Kane Biotech Inc.
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, March 15, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane...
Kane Biotech Announces New Collaboration Agreements for Prosthetic Joint Infection, expanding its DispersinB® applications
10. Februar 2022 08:00 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. announces that it has signed collaboration agreements with Dr. James Doub, MD, Assistant Professor of Medicine, University of...
Wound Care Commercialization to be a Key Company Focus in 2022
20. Januar 2022 12:00 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Kane Biotech CEO, Marc Edwards sees its rich 20-year history of biofilm research and product development as a real strategic advantage in the...
Kane Biotech Announces Third Quarter 2021 Financial Results
16. November 2021 16:00 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), today announced their third quarter 2021 financial results. ...
Kane Biotech to Release Third Quarter 2021 Financial Results on November 16 – Conference Call to Follow
09. November 2021 08:00 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and...
Kane Biotech Announces New Credit Facility
02. September 2021 08:00 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the “Company” or “Kane Biotech”), today announces that it has entered into an amended and restated...